14 results
424B4
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
23 Nov 20
Prospectus supplement with pricing info
4:36pm
therapy development lifecycle. For example, our mRNA products are used in drug development to assist in the production of immune-activating antigens; our … by providing inputs that are central to the performance of their products and processes throughout the product lifecycle. By collaborating
DRS/A
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
14 Oct 20
Draft registration statement (amended)
12:00am
development lifecycle. For example, our mRNA products are used in drug development to assist in the production of immune-activating antigens; our CleanCap® … of their products and processes throughout the product lifecycle. By collaborating with customers early in the development phase, our products
DRS/A
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
23 Oct 20
Draft registration statement (amended)
12:00am
portfolio offers key products for each stage of the cell and gene therapy development lifecycle. For example, our mRNA products are used in drug … that are central to the performance of their products and processes throughout the product lifecycle. By collaborating with customers early in the development phase
DRS
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
8 Sep 20
Draft registration statement
12:00am
consultants and management estimates. Our portfolio offers key products for each stage of the cell and gene therapy development lifecycle. For example, our … to the performance of their products and processes throughout the product lifecycle. By collaborating with customers early in the development phase, our
S-1
snq3y39gisq
29 Oct 20
IPO registration
5:04pm
10-Q
or6f7
12 May 21
Quarterly report
4:26pm
10-K
djare 0i39m2
22 Mar 21
Annual report
4:22pm
424B4
4soa7
9 Apr 21
Prospectus supplement with pricing info
4:02pm
DRS
s3f6ltu06dh
25 Mar 21
Draft registration statement
12:00am
- Prev
- 1
- Next